Pharma Pulse 5/15/24: Rethinking the Complex Process for Cancer Trials, OpenAI Launches Voice Assistant & more

Rethinking the Complex Process for Cancer Trials

Faced with a host of variables inherent to oncology studies, researchers look to inventive ways to boost efficiencies—and hopeful improved patient access.

Starting MS Treatment with Mild-to-Moderate Efficacy DMT More Likely to Result in Switch to High-Efficacy DMT

This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.

OpenAI Launches Voice Assistant Inspired by Hollywood Vision of AI

The function is part of a faster, more capable version of the company’s flagship artificial-intelligence model.

Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit

Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access.

Miranda Schmalfuhs on LinkedIn:

Check out my recent conversation with Amanda Powers Han of Greater Than One (also a member of the PE EAB!) about improving DE&I in healthcare marketing to reach diverse audiences on a deeper level.

Listen below!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs